Patent ID: 8415333
Filing Date: 2013-04-09
Classification: A61P,C07D

Abstract:
1. A compound according to formula (I), wherein R A is NR E is selected from the group consisting of C1-C3 alkylene, ethene-1,2-diyl, 1-propene-1,3-diyl and 2-propene-1,3-diyl; if E is selected from the group consisting of ethene-1,2-diyl, 1-propene-1,3-diyl and 2-propene-1,3-diyl, then the stereochemistry of the double-bond may be either E or Z; the integer “p” is 0 (zero), 1 or 2; R3 is independently selected from the group consisting of C1-C3 alkyl, C1-C3 alkyleneOC0-C3 alkyl, OMe, C1-5 fluoroalkyl, C0-C3 alkyleneOC1-3 fluoroalkyl, C(O)OC0-C3 alkyl, and C(O)N(C0-C3 alkyl) R3 may, if present, be connected to any of the carbon atom(s) in E; if “p” is 2, then the two R3 may be the connected to the same carbon atom or to different carbon atoms; Cy1 is a 5-membered heteroaryl, a 6-membered heteroaryl, or phenyl; the integer “n” is 0 (zero), 1 or 2; R4 is independently selected from the group consisting of C1-8 alkyl, C1-5 fluoroalkyl, halo, C0-1 alkylene cyano, C0-8 alkyleneOC0-5 alkyl, SC0-5 alkyl, C0-3 alkyleneSO R6, R7, and R8 are independently selected from the group consisting of H, halogen, C1-C3 alkyl, NH(C0-C3 alkyl), C1-3 fluoroalkyl, OC0-C3 alkyl, OC1-3 fluoroalkyl, N(C4-5 alkylene), morpholinyl, N(C1-C3 alkyl) R9 is selected from the group consisting of H, halogen, C1-C3 alkyl, and C1-3 fluoroalkyl; as a free base, an acid in its non-charged protonated form, a pharmaceutically addition acceptable salt, a pure stereoisomer, a racemic, diastereomeric or scalemic mixture, a corresponding tautomeric form resulting from a hydrogen shift between two hetero-atoms and/or the corresponding tautomeric form resulting from a keto-enol tautomerization; with the proviso that the compound is not any of the following: